Genomic DNA of CD34+ hematopoietic stem and progenitor cells (CD34+ HSPC genomic DNA)

The genomic DNA of CD34+ hematopoietic stem and progenitor cells (HSPCs) serves as the fundamental genetic blueprint for the entire blood and immune system (NIH, 2023). In the context of advanced therapeutics, this genomic DNA is the primary substrate for ex vivo gene editing and gene therapy interventions aimed at curing hereditary blood disorders (Nature Medicine, 2022). By targeting specific loci within the HSPC genome, such as the BCL11A erythroid enhancer or the HBB gene, clinicians can permanently alter the genetic output of a patient's hematopoietic lineage (FDA, 2023). These modifications are typically executed using CRISPR/Cas9 systems for precise deletions or lentiviral vectors for the integration of functional gene copies. Because HSPCs possess the unique ability to self-renew and differentiate, any genomic modification made to these cells is sustained throughout the patient's lifetime and propagated to all daughter cells, including erythrocytes and leukocytes (PubMed, 2021). However, the use of the entire genome as a target presents significant challenges, including the risk of off-target mutations or insertional mutagenesis that could lead to clonal expansion or malignancy (New England Journal of Medicine, 2021).

Other names

CD34+ HSPC DNAHematopoietic stem cell genomeHSPC genomic DNAGenomic DNA of CD34-positive hematopoietic stem cells

Gene editing (CRISPR/Cas9) to disrupt regulatory elements or gene addition (lentiviral vector) to integrate functional genetic sequences into the host cell genome.